Renaissance Technologies
EGRX

Renaissance Technologies’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Renaissance Technologies’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-256,350
Closed -$956K – 4020
2024
Q3 		$956K Buy
256,350
+12,100
+5% +$57.7K ﹤0.01% 2472
2024
Q2 		$1.37M Sell
244,250
-89,600
-27% -$390K ﹤0.01% 2131
2024
Q1 		$1.75M Buy
333,850
+39,400
+13% +$216K ﹤0.01% 2120
2023
Q4 		$1.54M Buy
294,450
+38,298
+15% +$378K ﹤0.01% 2108
2023
Q3 		$4.04M Sell
256,152
-4,321
-2% -$77.6K 0.01% 1426
2023
Q2 		$5.06M Buy
260,473
+51,623
+25% +$1.22M 0.01% 1425
2023
Q1 		$5.92M Sell
208,850
-57,800
-22% -$1.72M 0.01% 1376
2022
Q4 		$7.79M Sell
266,650
-7,629
-3% -$243K 0.01% 1243
2022
Q3 		$7.25M Buy
274,279
+21,300
+8% +$782K 0.01% 1210
2022
Q2 		$11.2M Buy
252,979
+39,400
+18% +$1.81M 0.01% 1045
2022
Q1 		$10.6M Buy
213,579
+5,800
+3% +$278K 0.01% 1092
2021
Q4 		$10.6M Buy
207,779
+5,500
+3% +$285K 0.01% 1037
2021
Q3 		$11.3M Buy
202,279
+5,400
+3% +$266K 0.01% 957
2021
Q2 		$8.43M Sell
196,879
-7,800
-4% -$322K 0.01% 1301
2021
Q1 		$8.54M Sell
204,679
-22,500
-10% -$1.04M 0.01% 1292
2020
Q4 		$10.6M Sell
227,179
-58,821
-21% -$2.75M 0.01% 1123
2020
Q3 		$12.1M Sell
286,000
-63,500
-18% -$2.78M 0.01% 1016
2020
Q2 		$16.8M Buy
349,500
+60,900
+21% +$3.04M 0.01% 927
2020
Q1 		$13.3M Buy
288,600
+131,900
+84% +$6.62M 0.01% 990
2019
Q4 		$9.41M Buy
156,700
+120,400
+332% +$7.18M 0.01% 1488
2019
Q3 		$2.05M Buy
+36,300
New +$2.04M ﹤0.01% 2270
2015
Q3 		– Sell
-23,400
Closed -$1.89M – 3411
2015
Q2 		$1.89M Sell
23,400
-36,500
-61% -$2.38M ﹤0.01% 2099
2015
Q1 		$2.51M Buy
+59,900
New +$1.7M 0.01% 1803

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Renaissance Technologies's EGRX Position: Q4 2024 in Review

Renaissance Technologies sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 256,350 shares — an estimated $956K sold.

Renaissance Technologies first reported a position in EGRX in Q1 2015 and held it in 23 quarters. The position peaked at $16.8M in Q2 2020. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Renaissance Technologies reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Renaissance Technologies sold 256,350 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $956K.
  • Renaissance Technologies first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 23 quarters.
  • Renaissance Technologies's Eagle Pharmaceuticals, Inc. position peaked at $16.8M in Q2 2020.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Renaissance Technologies's 13F filing for Q4 2024, filed 13 Feb 2025.